BOTHELL, Wash.--(BUSINESS WIRE)--Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has completed filing 83 patent applications (79 international applications and 4 U.S. applications) directed toward 144 different genes with siRNA’s designed and modified using Nastech’s proprietary RNAi technologies. These gene targets are disease-validated against cancer, inflammatory disease, and metabolic disorders. Overall, these patent applications are directed toward tens of thousands of targets.
